Company Focus
AstraZeneca
Latest AstraZeneca News
Pharmaceutical
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in the USA for the treatment of adults with previously untreated mantle cell lymphoma (MCL). 3 October 2024
Related News
Insights
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Latest News & Features of interest to AstraZeneca
Pharmaceutical
Danish pharma major Novo Nordisk was trading nearly 4% lower on Wednesday afternoon after earlier presenting its latest quarterly financial results and guidance for the rest of 2024. 7 August 2024
Pharmaceutical
The US Food and Drug Administration approved French privately-held drug major Servier’s vorasidenib, now trade named Voranigo, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for certain types of brain tumors. 7 August 2024
Pharmaceutical
A jury in an Illinois state court has found that UK drugmaker GSK (LSE: GSK) is not liable for causing a plaintiff’s colorectal cancer. 7 August 2024
Biotechnology
US biotech major Amgen reported second quarter 2024 financial results late yesterday, showing total revenues increased 20% to $8.4 billion in comparison to the like quarter of 2023. 7 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
US clinical-stage biotech Equillium saw its shares rise 8% to $0.68 as it revealed progress with its first-in-class anti-CD6 monoclonal antibody. 6 August 2024
Biotechnology
Daiichi Sankyo (and US pharma giant Merck & Co have expanded their existing global co-development and co-commercialization agreement to include Merck’s MK-6070. 6 August 2024
Biotechnology
Shares of Swiss antibody drug conjugates (ADCs) develop ADC Therapeutics were down more than 11% at $2.55 as it reported financial results for 2nd-qtr 2024 and provided operational updates. 6 August 2024
Pharmaceutical
Germany’s Bayer has reported group revenue of 11.1 billion euros ($12.2 billion) in the second quarter of 2024, ahead of the 10.9 billion euros average of analysts’ estimates and up by 1% on the same period a year ago. 6 August 2024
Biotechnology
Actinium Pharmaceuticals’ shares closed down 60% yesterday and fell a further 10% to $2.23 in after-hours trading, when the company announced a regulatory setback for its Iead candidate. 6 August 2024
Latest In Brief for AstraZeneca
Pharmaceutical
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Latest Related Ones To Watch News
Bristol Myers Squibb has scored a major legal victory as a judge in New York dismissed a $6.4 billion lawsuit related to its acquisition of cancer company Celgene. 1 October 2024
24 September 2024
24 September 2024
19 September 2024
5 September 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze